Effect of Sulforaphane on Bladder Compliance in a Rat Model of Partial Bladder Outlet Obstruction.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
11
2018
revised:
17
02
2019
accepted:
06
03
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
7
1
2020
Statut:
epublish
Résumé
To investigate the effect of Nrf2 activator sulforaphane (SFN) on bladder compliance and the underlying mechanisms in a rat model of partial bladder outlet obstruction (BOO). Male 8-week-old Sprague-Dawley rats were divided into three groups. BOO rats were given daily 0.5 mg/kg sulforaphane (BOO+SFN) or vehicle (BOO) intraperitoneally for 4 weeks, while sham-operated rats were treated with vehicle (Sham). Bladder compliance, histological alteration, and collagen deposition were evaluated. The expression levels of collagen I, collagen III, MMP-1, and TIMP-1 were measured by immunohistochemistry and western blotting. BOO led to a significant decrease in bladder compliance. The change was partially restored by SFN treatment. The expression of MMP-1 was significantly decreased accompanying with increased TIMP-1 expression in BOO rats compared with that in Sham rats, which was ameliorated by SFN treatment. Moreover, the increased collagen I/collagen III ratio in the BOO group was reversed by SFN treatment. Sulforaphane suppressed collagen deposition by regulating the MMP-1 and TIMP-1 expression and decreasing the collagen I/III expression ratio in BOO rats and improved bladder compliance.
Identifiants
pubmed: 31316719
doi: 10.1155/2019/6026719
pmc: PMC6604416
doi:
Substances chimiques
Isothiocyanates
0
Sulfoxides
0
Tissue Inhibitor of Metalloproteinase-1
0
Collagen
9007-34-5
Matrix Metalloproteinase 1
EC 3.4.24.7
sulforaphane
GA49J4310U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6026719Références
J Biol Chem. 1999 Jul 30;274(31):21491-4
pubmed: 10419448
In Vitro Cell Dev Biol Anim. 2003 Mar-Apr;39(3-4):157-62
pubmed: 14505431
Int J Clin Pract. 2007 Aug;61(8):1294-300
pubmed: 17627708
BJU Int. 2012 Aug;110(3):413-9
pubmed: 22115428
Int J Urol. 2012 Jan;19(1):20-5
pubmed: 22146061
J Vis Exp. 2012 Aug 09;(66):null
pubmed: 22907252
Urology. 2012 Dec;80(6):1390.e7-12
pubmed: 22990063
BJU Int. 2013 Aug;112(4):E391-7
pubmed: 23305285
Urology. 2014 Mar;83(3):675.e7-11
pubmed: 24581543
BJU Int. 2014 Dec;114(6):946-54
pubmed: 25116295
Cell Signal. 2015 Feb;27(2):215-27
pubmed: 25451078
Neurourol Urodyn. 2016 Mar;35(3):377-81
pubmed: 25557558
Neurourol Urodyn. 2016 Apr;35(4):444-9
pubmed: 25703926
Oxid Med Cell Longev. 2016;2016:7598294
pubmed: 27433291
In Vitro Cell Dev Biol Anim. 2017 Jan;53(1):58-66
pubmed: 27632054
World J Urol. 2017 Aug;35(8):1247-1254
pubmed: 28013345
Oxid Med Cell Longev. 2018 Jul 22;2018:1393641
pubmed: 30140361
Acta Biomater. 2019 Mar 15;87:97-107
pubmed: 30708064
J Urol. 1984 Sep;132(3):474-9
pubmed: 6206240
Am J Physiol. 1997 Jun;272(6 Pt 2):R1960-5
pubmed: 9227614